Description

Stockholm3 Prostate Cancer Test

Stockholm3 is a blood test that helps to predict risk of clinically significant prostate cancer in men aged 45–75 years with a PSA level greater than 1.5 ng/ml where no previous diagnosis of prostate cancer has been made.

Stockholm3 combines PSA with three other protein markers, a range of genetic markers and clinical information to provide a more accurate risk calculation than
PSA alone. The results are personalised on the basis of age and family history, enabling an individual risk assessment. This approach ensures that people who are at high risk, but have a low PSA level, are identified at an early stage through further investigation. This prevents diagnoses from being made too late and
expands the range of potential treatments.
The test includes a clear recommendation for action, which makes it easier to interpret the results and determine the next diagnostic steps.

This means that in most cases patients can be treated safely and in a resource-efficient manner by their GP without being referred to a urologist.

The Stockholm3 test is a blood test for the early detection of prostate cancer.
The innovative test makes it possible to detect prostate carcinoma at a very early stage.

Stockholm3 combines protein markers (free and total PSA, PSP94, GDF15 and KLK2) with a range of genetic markers and clinical data (age, family history of
prostate cancer, previous biopsies, use of 5-alpha-reductase inhibitors) in an algorithm with the aim of detecting aggressive prostate cancer at an early stage

Click the link below to learn more about Prostate Cancer!